Adedayo A. Onitilo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adedayo A. Onitilo has a total of 405 co-authors. Here are the top co-authors by number of shared publications:
- Mark E. Burkard
University of Wisconsin–Madison 1 McArdle Laboratory for Cancer Research Madison, Wisconsin
104 shared publications - Benjamin M. Parsons
Gundersen Health System, La Crosse, Wisconsin, United States
103 shared publications - Daniel H. Hovelson
Strata Oncology, Ann Arbor, MI
103 shared publications - Eddy Shih-Hsin Yang
Department of Radiation Medicine, University of Kentucky, Lexington, KY, USA
103 shared publications - Kat Kwiatkowski
Strata Oncology, Ann Arbor, MI
103 shared publications - Robert D. Siegel
Bon Secours St Francis Cancer Center, Greenville, SC
103 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (4) , 101908
Circulating tumor DNA predicts tumor recurrence in early-stage breast cancer: A meta-analysis
- 1 July 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (4) , 101908
Open AccessCirculating tumor DNA predicts tumor recurrence in early-stage breast cancer: A meta-analysis
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Subprotocol C1: Adverse Events Related to Treatment.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Subprotocol C1: Adverse Events Related to Treatment.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Subprotocol C1 co-occurring mutation plot
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Subprotocol C1 co-occurring mutation plot
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Subprotocol C1: Details on Cases with Confirmed PR or PFS >6 months
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Subprotocol C1: Details on Cases with Confirmed PR or PFS >6 months
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Subprotocol C2 co-occurring mutation plot
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Subprotocol C2 co-occurring mutation plot
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Subprotocol C2: Adverse Events Related to Treatment
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Subprotocol C2: Adverse Events Related to Treatment
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Purpose:The NCI-MATCH trial enrolled patients to subprotocols C1 and C2 to evaluate the METtyrosine kinase inhibitor crizotinib for efficacy in patients with MET amplification (METamp; C1) or MET exon 14 skipping mutation (METex14; C2).Patients and Methods:Tumors harboring METamp or METex14 were confirmed by Oncomine assay, RNA sequencing, and anchored multiplex PCR. Patients received 250 mg crizotinib orally daily until disease progression or unacceptable toxicity. Primary endpoint was objective response rate (ORR); secondary endpoints included progression-free survival (PFS), 6-month PFS, and overall survival (OS).Results:C1 efficacy analysis comprised 28 of 44 enrolled patients (17 gastrointestinal, seven lung, and four other tumor types). Four patients had a partial response (PR), 10 had stable disease (SD), and 13 had progressive disease (PD); one was unevaluable. The ORR was 14% [four of 28; 90% confidence interval (CI), 5%–29.8%]. The median PFS (mPFS) was 3.4 months (90% CI, 1.8–3.7), and the median OS (mOS) was 7.1 months (90% CI, 5–11.5). C2 included 14 of 20 patients (five gastrointestinal, six lung, and three other). Two patients had PR, four SD (2 > 6 months), and four PD were observed. The ORR was 14% (two of 14; 90% CI, 2.6%–38.5%). mPFS and mOS were 2 months (90% CI, 1.4–4.1) and 10.2 months (90% CI, 2.3–19.6). METex14 cases with read count ≥50,000 had mPFS 8.8 months [90% CI, 2.1–NR(not reached)] versus 1.7 months (90% CI, 1.1–3.7).Conclusions:Crizotinib demonstrated clinical activity across tumors with METamp and METex14. Subprotocol C1, but not C2, met its primary endpoint. In METex14 disease, a read count cutoff >50,000 may help distinguish true pathogenic variants from low-level splice transcripts and enable more accurate classification.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Purpose:The NCI-MATCH trial enrolled patients to subprotocols C1 and C2 to evaluate the METtyrosine kinase inhibitor crizotinib for efficacy in patients with MET amplification (METamp; C1) or MET exon 14 skipping mutation (METex14; C2).Patients and Methods:Tumors harboring METamp or METex14 were confirmed by Oncomine assay, RNA sequencing, and anchored multiplex PCR. Patients received 250 mg crizotinib orally daily until disease progression or unacceptable toxicity. Primary endpoint was objective response rate (ORR); secondary endpoints included progression-free survival (PFS), 6-month PFS, and overall survival (OS).Results:C1 efficacy analysis comprised 28 of 44 enrolled patients (17 gastrointestinal, seven lung, and four other tumor types). Four patients had a partial response (PR), 10 had stable disease (SD), and 13 had progressive disease (PD); one was unevaluable. The ORR was 14% [four of 28; 90% confidence interval (CI), 5%–29.8%]. The median PFS (mPFS) was 3.4 months (90% CI, 1.8–3.7), and the median OS (mOS) was 7.1 months (90% CI, 5–11.5). C2 included 14 of 20 patients (five gastrointestinal, six lung, and three other). Two patients had PR, four SD (2 > 6 months), and four PD were observed. The ORR was 14% (two of 14; 90% CI, 2.6%–38.5%). mPFS and mOS were 2 months (90% CI, 1.4–4.1) and 10.2 months (90% CI, 2.3–19.6). METex14 cases with read count ≥50,000 had mPFS 8.8 months [90% CI, 2.1–NR(not reached)] versus 1.7 months (90% CI, 1.1–3.7).Conclusions:Crizotinib demonstrated clinical activity across tumors with METamp and METex14. Subprotocol C1, but not C2, met its primary endpoint. In METex14 disease, a read count cutoff >50,000 may help distinguish true pathogenic variants from low-level splice transcripts and enable more accurate classification.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Representativeness of Study Participants
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2
Representativeness of Study Participants